Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för dacomitinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2016-06-11

Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).

Prawira A, Brana-Garcia I, Spreafico A, Hope A, Waldron J, Razak AR, Chen EX, Jang R, O'Sullivan B, Giuliani M, Bayley A, Cho J, Wang L, Perez-Ordonez B, Weinreb I, Siu LL, Hansen AR.

Invest New Drugs · clinical trial, phase i; journal article · DOI 10.1007/s10637-016-0367-2

Bibliografisk träff 2016-05-03

Current Role of Dacomitinib in Head and Neck Cancer.

Elicin O, Ozsahin M.

Expert Opin Investig Drugs · review; journal article · DOI 10.1080/13543784.2016.1177022

Bibliografisk träff 2016-02-18

Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.

Jänne PA, Shaw AT, Camidge DR, Giaccone G, Shreeve SM, Tang Y, Goldberg Z, Martini JF, Xu H, James LP, Solomon BJ.

J Thorac Oncol · multicenter study; clinical trial, phase i; journal article · DOI 10.1016/j.jtho.2016.01.022

Bibliografisk träff 2016-01-20

Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer.

Créquit P, Trinquart L, Yavchitz A, Ravaud P.

BMC Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12916-016-0555-0

Bibliografisk träff 2016-01-13

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L.

Ann Oncol · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1093/annonc/mdv593

Bibliografisk träff 2015-10-09

Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.

Ruiz-Garcia A, Masters JC, Mendes da Costa L, LaBadie RR, Liang Y, Ni G, Ellery CA, Boutros T, Goldberg Z, Bello CL.

J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/jcph.588

Bibliografisk träff 2015-02-11

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Tumour Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s13277-015-3218-4

Bibliografisk träff 2014-05-22

Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.

Williams JP, Kim I, Ito E, Shi W, Yue S, Siu LL, Waldron J, O'Sullivan B, Yip KW, Liu FF.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0098557

Bibliografisk träff 2012-07-03

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.

Mol Cancer Ther · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1158/1535-7163.mct-11-0730

Bibliografisk träff 2012-07-02

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M.

J Clin Oncol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2011.40.9433